

THE HF QUEST


DECODING THE EVIDENCE TO TRANSFORM HEART FAILURE OUTCOMES

Friday, October 25, 2019
12:30 - 1:30 pm

Room 517C, Level 5,
Palais des congrès de Montréal,
Montreal, QC



Claim in-room
Section 3 credits



CONNECT THE CLUES TO BETTER:

- Discuss the outcomes of recent late-breaking heart failure trials, including PARAGON
- Implement practical recommendations for timely identification and management of acute decompensated heart failure
- Recognize the importance of optimizing heart failure treatment in the acute hospital setting

JOIN THE INVESTIGATION TEAM

Chair



Shelley Zieroth, MD, FRCPC, FCCS
Associate Professor of Medicine, Cardiology,
University of Manitoba
Director, St. Boniface Hospital HF and Transplant Clinics
President Canadian Heart Failure Society



Scott D. Solomon, MD
Professor of Medicine, Harvard Medical School
Director, Noninvasive Cardiology,
Brigham and Women's Hospital
Director, Cardiac Imaging Core Laboratory &
Clinical Trials Endpoints Center



Abhinav Sharma, MD, PhD, FRCPC
Assistant Professor of Medicine, Cardiology,
McGill University
Junior Scientist, RI-MUHC, Glen Site
Lead, MUCH Digital Health Initiative



Heather J. Ross, MD, FRCPC, FACC
Professor of Medicine, University of Toronto
Cardiologist, Peter Munk Cardiac Centre
Affiliate Scientist, Toronto General Hospital Research Institute
Director, Cardiac Transplant Program, Toronto General Hospital
Chair, Ted Rogers Centre of Excellence in Heart Function



Anil Gupta, MD, FRCPC
Staff Cardiologist, Trillium Health Partners
Physician Lead, Cardiac Diagnostics and Rehabilitation
Cardiology Lead, Undergraduate Education
Mississauga Academy of Medicine
Lecturer, University of Toronto

This event is an Accredited Self-Assessment Program under Section 3 as defined by the Royal College of Physicians & Surgeons of Canada for the Maintenance of Certification program and has been approved by the Canadian Cardiovascular Society.

This program was co-developed with the Canadian Cardiovascular Society and Novartis Pharmaceuticals Canada Inc. and was planned to achieve scientific integrity, objectivity and balance.

This program was made possible through an educational grant from Novartis Pharmaceuticals Canada Inc.

